The Systematic Research of The Comparison of Moderna Covid-19 Vaccine and Pfizer Covid-19 Vaccine
DOI:
https://doi.org/10.54097/hset.v45i.7384Keywords:
Vaccine; COVID-19; SARS-CoV-2; Pfizer; Moderna.Abstract
The outbreak of the one-of-a-kind coronavirus in March of the year 2020 was designated as a pandemic by the World Health Organization. This article will cover the mechanism of action, mode of administration, adverse effects, and effectiveness of the Pfizer and Moderna created mRNA COVID-19 vaccine, which is licensed for use in the United States, as well as current times. In addition, the evolution of the illness is going to be covered in this article. Pfizer and Moderna, respectively, have created mRNA vaccines that encode the SARS-CoV-2 spike-in protein in order to combat the SARS-CoV-2 outbreak. Since the United States government issued an emergency permission to administer the vaccine there, both those who took part in clinical trials and members of the general public have shown that the vaccine is safe to use. Pfizer and Moderna's SARS-CoV-2 vaccines have been demonstrated to be 95.0% effective in avoiding infections that are regarded as being mild or symptomatic. Because these vaccinations are now the subject of ongoing clinical research, it is essential to have access to medical literature that has been brought up to date. This is especially significant when they are researched in a variety of age groups as well as when new strains of SARS-CoV-2 coronavirus develop. In addition to this, the article presents a succinct review of the future of mRNA vaccines, and it makes the statement that mRNA vaccines will play a significant position in the creation of future human vaccines.
Downloads
References
Coronaviridae Study Group of the International Committee on Taxonomy of Viruses (Alexander E Gorbalenya, Susan C Baker, Ralph S Baric, Raoul J de Groot, Christian Drosten, Anastasia A Gulyaeva, Bart L Haagmans, Chris Lauber, Andrey M Leontovich, Benjamin W Neuman, Dmitry Penzar, Stanley Perlman, Leo L M Poon, Dmitry V Samborskiy, Igor A Sidorov, Isabel Sola, John Ziebuhr). The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020 Apr;5(4):536-544.
Lovelace, Berkeley Jr. (18 June 2021). "WHO says delta is becoming the dominant Covid variant globally". CNBC. Retrieved 1 November 2021. https://www.cnbc.com/2021/06/18/who-says-delta-is-becoming-the-dominant-covid-variant-globally.html
Wikipedia contributors. (2023, January 3). SARS-CoV-2 Delta variant. In Wikipedia, The Free Encyclopedia. Retrieved 21:18, January 14, 2023, from https://en.wikipedia.org/w/index.php?title=SARS-CoV-2_Delta_variant&oldid=1131367992
Nhamo G, Chikodzi D, Kunene HP, Mashula N. COVID-19 vaccines and treatments nationalism: Challenges for low-income countries and the attainment of the SDGs. Glob Public Health. 2021 Mar;16(3):319-339.
Pfefferbaum B, North CS. Mental Health and the Covid-19 Pandemic. N Engl J Med. 2020 Aug 6;383(6):510-512.
Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed. 2020 Mar 19;91(1):157-160.
Hadj Hassine I. Covid-19 vaccines and variants of concern: A review. Rev Med Virol. 2022 Jul;32(4):e2313.
Matthew Cobb, who discovered messenger RNA, Current Biology, Volume 25, Issue 13, 2015, Pages R526-R532, ISSN 0960-9822.
Wolff, J. A. et al. Direct gene transfer into mouse muscle in vivo. Science 247, 1465–1468 (1990).
Moderna. Emergency use authorization (EUA): moderna COVID-19 Vaccine. Moderna. Published 2021. [Accessed 2021 Mar 16]. https://www.modernatx.com/covid19vaccine-eua/
Zhang C, Maruggi G, Shan H, Li J. Advances in mRNA Vaccines for Infectious Diseases. Front Immunol. 2019 Mar 27; 10:594.
Bettini E, Locci M. SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond. Vaccines (Basel). 2021 Feb 12;9(2):147.
Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott A, Flach B, Doria-Rose NA, Corbett KS, Morabito KM, O'Dell S, Schmidt SD, Swanson PA 2nd, Padilla M, Mascola JR, Neuzil KM, Bennett H, Sun W, Peters E, Makowski M, Albert J, Cross K, Buchanan W, Pikaart-Tautges R, Ledgerwood JE, Graham BS, Beigel JH; mRNA-1273 Study Group. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020 Nov 12;383(20):1920-1931.
Jain S, Venkataraman A, Wechsler ME, Peppas NA. Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic. Adv Drug Deliv Rev. 2021 Dec; 179:114000.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec 31;383(27):2603-2615.
Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, AlMukdad S, Coyle P, Ayoub HH, Al Kanaani Z, Al Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul Rahim HF, Nasrallah GK, Al Kuwari MG, Al Romaihi HE, Butt AA, Al-Thani MH, Al Khal A, Bertollini R, Abu-Raddad LJ. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat Med. 2021 Dec;27(12):2136-2143.
Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, Stowe J, Tessier E, Groves N, Dabrera G, Myers R, Campbell CNJ, Amirthalingam G, Edmunds M, Zambon M, Brown KE, Hopkins S, Chand M, Ramsay M. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021 Aug 12;385(7):585-594.
Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, Brooks N, Smaja M, Mircus G, Pan K, Southern J, Swerdlow DL, Jodar L, Levy Y, Alroy-Preis S. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021 May 15;397(10287):1819-1829.
Galang R R, Newton S M, Woodworth K R, et al. Risk factors for illness severity among pregnant women with confirmed SARS-CoV-2 infection–Surveillance for Emerging Threats to Mothers and Babies Network, 20 state, local, and territorial health departments, March 29, 2020-January 8, 2021 [J]. medRxiv, 2021. https://www.medrxiv.org/content/10.1101/2021.02.27.21252169v1
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T; COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 Feb 4;384(5):403-416.
Edara V V, Pinsky B A, Suthar M S, et al. Infection and vaccine-induced neutralizing-antibody responses to the SARS-CoV-2 B. 1.617 variants [J]. New England Journal of Medicine, 2021, 385(7): 664-666.
Puranik A, Lenehan P J, Silvert E, et al. Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence [J]. MedRxiv, 2021. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366801.2/
Dolgin E. How COVID unlocked the power of RNA vaccines. Nature. 2021 Jan;589(7841):189-191.
Mark Terry, “UPDATED Comparing COVID-19 Vaccines: Timelines, Types and Prices,” BioSpace,2021.https://www.biospace.com/article/comparing-covid-19-vaccines-pfizer-biontech-moderna-astrazeneca-oxford-j-and-j-russia-s-sputnik-v/
COVID P B N T. Vaccine Information| CDC [J]. Centers for Disease Control. 2020Available at: https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/index.html Accessed January 19, 2: 2021.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
